Arcutis biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Westlake village, calif., jan. 06, 2025 (globe newswire) -- arcutis biotherapeutics, inc.  (nasdaq: arqt), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 75,500 restricted stock units of arcutis' common stock to eight newly hired employees. these awards were approved by the compensation committee of arcutis' board of directors and granted under the arcutis biotherapeutics, inc. 2022 inducement plan, with a grant date of january 2, 2025, as an inducement material to the new employees entering into employment with arcutis, in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking